Heather Wakelee, MD, FASCO
Professor of Medicine and Chief of the Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, California
Gerald Berry, MD
Richard Kempson, MD Professor of Surgical Pathology
Stanford University School of Medicine
Director of Cardiac and Pulmonary Pathology
Stanford Medicine
Stanford, California

Target Audience

The educational design of this activity addresses the needs of oncology, interventional radiology, oncology pharmacy, and pathology clinicians (MDs, PAs, NPs, and nurses) involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Program Description

With a variety of available targeted therapies, it is crucial for clinicians to prioritize molecular testing soon after a diagnosis of NSCLC. In addition to a 3D animation overview of the EGFR mutations that affect therapeutic decision-making in advanced and metastatic NSCLC, Dr. Heather Wakelee and Dr. Gerald Berry outline the roles of tissue and liquid biopsy and strategies to optimize needle biopsy tissue samples in unresectable NSCLC. 

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate mutational status in patients with NSCLC using appropriate molecular testing techniques
  • Describe the pathophysiology and clinical implications of EGFR mutations in NSCLC

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.


Credit Designation

Global Education Group designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education (Universal Activity Number - 0530-9999-23-055-H01-P).

This is a knowledge-based activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour(s) (which includes 0.0 hour[s] of pharmacology).

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 100% on the posttest and complete the program evaluation. Pharmacists must check the CPE Monitor for credits within 60 days of the activity. Credit for pharmacists cannot be issued after 60 days.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Heather Wakelee, MD, FASCO: Consulting Fee: Mirati (served on DSMC); Contracted Research: Arrys Therapeutics, AstraZeneca, Bayer, BMS, Clovis, Genentech/Roche, Helsinn, Merck, Novartis, Seagen, Xcovery

Gerald Berry, MD: Nothing to disclose

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Begin Activity
available resources
interactive presentation
linked resources
Suggested Reading
CME Snapshot™ Series

Hitting the Bullseye in NSCLC

Updates on EGFR-Targeting Therapies